Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

Inclusion criteria: Primary non-small cell lung cancer confirmed by cytology and histology, excluding sputum examination; Phase IIIB/IV based on TNM criteria (8th); At least one measurable tumor based on RECIST 1.1; Without the known active mutation of EGFR/ALK/ROS1/RET; Male or female, age≥18 or ≤70 years old; ECOG PS: 0 or 1; Estimated time of survival: ≥ 3 months; Suitable hematologic function: ANC≥2×109/L, PLC≥100×109/L and Hb≥9 g/dL; Suitable liver function: Total bilirubin≤ normal ULN, AST and ALT≤2.5×normal ULN, ALP≤ 5×normal ULN; Suitable renal function: Cr≤normal ULN,or Ccr≥60 ml/min; EKG normal; Without healing wound; No history of anti-cancer therapy, or adjuvant/neo-adjuvant chemotherapy for non-metastatic tumor finished for more than 6 months before enrollment; For the female subject with productive ability, urine pregnancy test must be done and is negative within 7 days before enrollment; No history of serious allergic to biologic agents, especially E.Coli products; The authorized ICF must be signed. Exclusion Criteria: Woman in pregnancy and breast-feeding, or having productive ability without contraception; Having the serious acute infection uncontrolled or purulent/chronic infection with unhealed wound; Having the serious heart disease, including congestive heart failure, uncontrolled high-risk arrhythmia, unstable angina, myocardial infarction, valvular disease, and refractory hypertension; Having uncontrolled nervous or mental disease with low compliance and reluctance to description of response; uncontrolled primary brain tumor or other metastatic brain cancer with obvious intracranial hypertension or mental symptoms; Having the tendency of bleeding, such as FIB≤2G/L; Being receiving adjuvant chemotherapy; On other conditions investigator considers, the subject is not fitful to participate the trial.